Advertisement

Topics

Aerpio Announces Initiation Of Patient Dosing In The TIME-2b Study, A Phase IIb Clinical Trial Of Lead Candidate AKB-9778 In Patients With Diabetic Retinopathy

20:00 EDT 28 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Aerpio Announces Initiation Of Patient Dosing In The TIME-2b Study, A Phase IIb Clinical Trial Of Lead Candidate AKB-9778 In Patients With Diabetic Retinopathy

NEXT ARTICLE

More From BioPortfolio on "Aerpio Announces Initiation Of Patient Dosing In The TIME-2b Study, A Phase IIb Clinical Trial Of Lead Candidate AKB-9778 In Patients With Diabetic Retinopathy"

Advertisement
Quick Search
Advertisement
Advertisement